Immuron Ltd — Board/Management Information 2012

Mar 4, 2012

==> picture [13 x 35] intentionally omitted <==

==> picture [54 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

==> picture [46 x 35] intentionally omitted <==

IMMURON APPOINTS CHIEF EXECUTIVE OFFICER

Melbourne 5 March 2012: Au s tralian bio p harmaceu t ical comp a ny Immur o n Limited ( A SX: IMC) announces th e appointm e nt of Mr J o e Baini as C hief Execu t ive Office r, effective immedia t ely. Previ o usly he held the posit i on in an in t erim capa c ity. His on g oing appoint m ent ensur e s uninterr u pted prog r ess of the c ompany’s c ommercia l isation an d develop m ent activities.

Mr Baini was appoi n ted Interi m CEO in Ja n uary 2011 and has be e n instrum e ntal in transfor m ing the co m pany over the last 1 2 months. U nder his guidance Immuron initiated and finalis e d the licen s e agreem e nt with Paladin Labs f o r Travelan , obtained IND approval from the FDA in the USA for Im m uron’s NA S H/Fatty Liver product (IMM‐124 E ), and gen e rated stro n g interest f rom major overseas c o mpanies i n both pro d ucts.

As well, r esearch and develop m ent has pr o gressed f o r other po s sible prod u cts to prevent and trea t influenza a nd C. diffi c ile infectio n s, through agreemen t s with the U niversity o f Melbour n e and Mo n ash Unive r sity, respe c tively.

Announcing the ap p ointment, c ompany C h airman Pr o fessor Colin Chapma n said “Joe’ s leadersh i p over the past year has been pi v otal to Im m uron’s co m mercial a n d product develop m ent strate g y, and the Board is d e lighted to h ave secur e d his ongo i ng service s . Joe’s experience wi t h local and global pha r maceutical companies will be es p ecially importa n t as Immu r on escalat e s negotiati o ns with multi‐nation a l compani e s.”

Mr Baini has over 2 0 years exp e rience in t h e pharma c eutical industry, focu s ed on commer c ialisation, including marketing, s a les, partn e rships, gov e rnment a n d licensing negotiations. He is t he former General M a nager of Gilead Scien c es Austral i a, New Zealand a nd Asia, o n e of the la r gest biopharmaceuti c al companies in the w o rld. During his five‐year tenure, Gilead tra n sformed f r om a fledg l ing organisation into a major pla y er within the infectiou s diseases m arkets. M r Baini has also held s e nior com m ercial manage m ent positi o ns at Bayer Australia, Pharmacia & Upjohn a nd Merck, and was Chairma n of Avexa L td.

Mr Baini, in accepti n g the app o intment, s a id: “While there are c h allenges ahead, Imm u ron has never been in a better posi t ion with it s product pipeline. There is growing interes t in both Tra v elan and I M M‐124E, w ith comm e rcial discu s sions and n egotiatio n s already underwa y with mul t inational c o mpanies. I look forw a rd to cont i nuing the w ork with Immuro n 's outstan d ing team t o commerc i alise new p roducts and expand m arkets.”

Contact

Colin Chapman +61 3 8637 110 7

Rudi Michel s on M onsoon C o mmunicati o ns +61 3 9620 3 333 0 4 11 402 737

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy‐derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre‐ clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travelers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).